OncoMatch/Clinical Trials/NCT07777536
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer
Is NCT07777536 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies non-drug interventions for thyroid cancer.
To explore the efficacy and safety of selective coverage radiotherapy in poorly differentiated and anaplastic thyroid cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Gland Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiotherapy to the head and neck or upper mediastinum
Exception: if the target area of this study does not overlap significantly and normal tissue limit can be met
Has received radiotherapy to the head and neck or upper mediastinum region in the past, and the target area of this study overlaps significantly with it, and the normal tissue limit cannot be met.
Lab requirements
Kidney function
severe dysfunction of the kidneys cannot be safely treated with radiotherapy
Liver function
severe dysfunction of the liver cannot be safely treated with radiotherapy
Cardiac function
severe dysfunction of the heart cannot be safely treated with radiotherapy
major organ functions can meet the requirements for radiotherapy and the proposed systemic treatment; severe dysfunction of the heart, lungs, liver, kidneys or other diseases that cannot be safely treated with radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07777536 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy to the head and neck or upper mediastinum disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages